What is BioGrammatics?
BioGrammatics, Inc. operates as a contract research organization (CRO) with a specialized focus on Pichia protein expression. The company empowers clients by offering proprietary tools and expert guidance for developing their own expression systems. Their product portfolio includes essential components like expression vectors, competent strains, and selection media. Furthermore, BioGrammatics provides comprehensive services ranging from gene optimization to genomic sequencing, crucial for regulatory submissions. Since its establishment in 2008, the company has been dedicated to supporting protein expression development across various projects, including those supported by the World Health Organization (WHO). A key innovation is their GlycoSwitch technology, which enables the modification of N-linked oligosaccharide structures through the use of glycoengineered Pichia strains, enhancing the utility and applicability of their protein expression solutions.
How much funding has BioGrammatics raised?
BioGrammatics has raised a total of $47K across 1 funding round:
Debt
$47K
Debt (2021): $47K with participation from PPP
What's next for BioGrammatics?
With the recent influx of substantial expansion capital, BioGrammatics is poised for accelerated growth and enhanced service delivery. The company's strategic positioning at the Series B/C stage suggests a focus on scaling its Pichia protein expression capabilities, potentially expanding its service offerings, and deepening its market penetration within the biopharmaceutical and biotechnology sectors. Future developments may include further refinement of its proprietary technologies, such as GlycoSwitch, and broadening its support for complex regulatory submissions, thereby solidifying its role as a key partner for organizations requiring advanced protein expression solutions.
See full BioGrammatics company page
